Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Pentosidine plasma levels and relation with metabolic control in diabetic patients.

Lapolla A, Reitano R, Baccarin L, Sartore G, Plebani M, Fedele D.

Horm Metab Res. 2005 Apr;37(4):252-6.

PMID:
15952087
2.

The effects of n-3 long-chain polyunsaturated fatty acid supplementation on AGEs and sRAGE in type 2 diabetes mellitus.

Kurt A, Andican G, Siva ZO, Andican A, Burcak G.

J Physiol Biochem. 2016 Dec;72(4):679-687. Epub 2016 Jul 22.

PMID:
27448155
3.

Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN).

Schiel R, Franke S, Appel T, Voigt U, Ross IS, Kientsch-Engel R, Stein G, Müller UA.

J Diabetes Complications. 2003 Mar-Apr;17(2):90-7.

PMID:
12614975
5.

Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.

Ghanem AA, Elewa A, Arafa LF.

Eur J Ophthalmol. 2011 Jan-Feb;21(1):48-54.

PMID:
20544678
6.

Evaluation of advanced glycation end products and carbonyl compounds in patients with different conditions of oxidative stress.

Lapolla A, Reitano R, Seraglia R, Sartore G, Ragazzi E, Traldi P.

Mol Nutr Food Res. 2005 Jul;49(7):685-90.

PMID:
15926142
7.

Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus.

Kanazawa I, Yamamoto M, Yamaguchi T, Sugimoto T.

Exp Clin Endocrinol Diabetes. 2011 Jun;119(6):362-5. doi: 10.1055/s-0030-1267953. Epub 2011 Apr 6.

PMID:
21472665
8.

Correlation between plasma pentosidine concentrations and retinal hemodynamics in patients with type 2 diabetes.

Sato E, Nagaoka T, Yokota H, Takahashi A, Yoshida A.

Am J Ophthalmol. 2012 May;153(5):903-909.e1. doi: 10.1016/j.ajo.2011.10.020. Epub 2012 Jan 21.

PMID:
22265156
9.
10.

Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.

Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, Van Ypersele de Strihou C, Kurokawa K.

J Am Soc Nephrol. 1998 Sep;9(9):1681-8.

12.

Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers.

Miyata T, Ishiguro N, Yasuda Y, Ito T, Nangaku M, Iwata H, Kurokawa K.

Biochem Biophys Res Commun. 1998 Mar 6;244(1):45-9.

PMID:
9514872
13.

Increased serum levels of pentosidine, but not carboxymethyl lysine, in type 2 diabetes without obvious diabetic nephropathy.

Daimon M, Ono Y, Saito T, Yamaguchi H, Hirata A, Ohnuma H, Igarashi M, Eguchi H, Manaka H, Kato T.

Diabetes Care. 1999 May;22(5):877-8. No abstract available.

14.

Pentosidine - a new biochemical marker in diabetic retinopathy.

Salman AG, Mansour DE, Swelem AH, Al-Zawahary WM, Radwan AA.

Ophthalmic Res. 2009;42(2):96-8. doi: 10.1159/000225661. Epub 2009 Jun 18.

PMID:
19546600
15.

[Pentosidine: a new biomarker in diabetes mellitus complications].

Morales S, García-Salcedo JA, Muñoz-Torres M.

Med Clin (Barc). 2011 Mar 19;136(7):298-302. doi: 10.1016/j.medcli.2009.12.001. Epub 2010 Mar 11. Review. Spanish.

PMID:
20226481
16.

The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.

Barzilay JI, Jablonski KA, Fonseca V, Shoelson SE, Goldfine AB, Strauch C, Monnier VM; TINSAL-T2D Research Consortium.

Diabetes Care. 2014 Apr;37(4):1083-91. doi: 10.2337/dc13-1527. Epub 2013 Nov 19.

17.

Glycated albumin as an improved indicator of glycemic control in hemodialysis patients with type 2 diabetes based on fasting plasma glucose and oral glucose tolerance test.

Nagayama H, Inaba M, Okabe R, Emoto M, Ishimura E, Okazaki S, Nishizawa Y.

Biomed Pharmacother. 2009 Mar;63(3):236-40. doi: 10.1016/j.biopha.2008.04.002. Epub 2008 May 15.

PMID:
18538530
18.
19.

Advanced glycation end products in children with chronic renal failure and type 1 diabetes.

Misselwitz J, Franke S, Kauf E, John U, Stein G.

Pediatr Nephrol. 2002 May;17(5):316-21.

PMID:
12042886
20.

High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control.

Neumann T, Lodes S, Kästner B, Franke S, Kiehntopf M, Lehmann T, Müller UA, Wolf G, Sämann A.

Osteoporos Int. 2014 May;25(5):1527-33. doi: 10.1007/s00198-014-2631-7. Epub 2014 Mar 6.

PMID:
24599273

Supplemental Content

Support Center